Nomura Holdings Inc. purchased a new position in shares of ABIOMED, Inc. (NASDAQ:ABMD) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 6,193 shares of the medical equipment provider’s stock, valued at approximately $888,000.
A number of other large investors have also made changes to their positions in ABMD. Parametric Portfolio Associates LLC boosted its stake in ABIOMED by 4.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 43,001 shares of the medical equipment provider’s stock valued at $5,384,000 after purchasing an additional 1,789 shares during the period. Envestnet Asset Management Inc. lifted its position in shares of ABIOMED by 21.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,221 shares of the medical equipment provider’s stock worth $404,000 after acquiring an additional 558 shares during the period. KBC Group NV bought a new stake in shares of ABIOMED in the 1st quarter worth approximately $388,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of ABIOMED in the 1st quarter worth approximately $244,000. Finally, Stifel Financial Corp lifted its position in shares of ABIOMED by 4.3% in the 1st quarter. Stifel Financial Corp now owns 3,918 shares of the medical equipment provider’s stock worth $496,000 after acquiring an additional 163 shares during the period. Hedge funds and other institutional investors own 89.49% of the company’s stock.
A number of equities analysts have recently issued reports on the company. Jefferies Group LLC increased their target price on ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a report on Friday, September 29th. Piper Jaffray Companies reissued a “buy” rating and issued a $160.00 target price on shares of ABIOMED in a report on Tuesday, August 29th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “strong-buy” rating and set a $163.00 price target for the company in a report on Thursday, July 13th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, August 10th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $200.00 price target (up from $180.00) on shares of ABIOMED in a report on Thursday, October 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $178.25.
WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/nomura-holdings-inc-buys-shares-of-6193-abiomed-inc-abmd.html.
In other news, Director Eric A. Md Rose sold 982 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total value of $142,556.94. Following the transaction, the director now owns 13,634 shares in the company, valued at $1,979,247.78. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Eric A. Md Rose sold 23,018 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $151.09, for a total transaction of $3,477,789.62. Following the transaction, the director now directly owns 24,652 shares of the company’s stock, valued at $3,724,670.68. The disclosure for this sale can be found here. Insiders have sold 61,782 shares of company stock worth $9,513,610 in the last three months. 7.00% of the stock is currently owned by insiders.
ABIOMED, Inc. (NASDAQ:ABMD) traded up 0.82% during mid-day trading on Friday, hitting $181.07. The company’s stock had a trading volume of 676,567 shares. The firm has a 50 day moving average of $166.04 and a 200-day moving average of $147.35. The firm has a market cap of $7.99 billion, a price-to-earnings ratio of 105.89 and a beta of 0.27. ABIOMED, Inc. has a 52-week low of $95.14 and a 52-week high of $183.96.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter in the previous year, the company earned $0.20 earnings per share. ABIOMED’s quarterly revenue was up 28.9% on a year-over-year basis. On average, equities research analysts expect that ABIOMED, Inc. will post $2.33 EPS for the current fiscal year.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.